AbbVie to Present Analysis Evaluating Continuous RINVOQ® Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
ABBVie today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ ® resulted in sustained improvements in disease activity for more than one year among patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs . 1 At week 56, 29 percent of patients treated with ...
Source: investingnews.com